US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
FCC fines wireless carriers for sharing user locations without consent
The Federal Communications Commission has leveraged nearly $200 million in fines against wireless ca2024-05-01Max Fried throws Atlanta's first 9
ATLANTA (AP) — Max Fried pitched a three-hitter for Atlanta’s first nine-inning complete game since2024-05-01Yobs armed with catapults terrorise a quiet Surrey village
A group armed with catapults are terrorising a quiet village in Surrey and made a funeral their late2024-05-01Tennessee passes bill to allow armed teachers in public schools
NASHVILLE, Tenn. (AP) — Protesters chanted “Blood on your hands” at Tennessee House Republicans on T2024-05-01‘Kraven the Hunter’ release delayed until December
The summer movie season may kick off next weekend, but the release calendar is still a work in progr2024-05-01Capital FM's reveals Nicki Minaj's major diva moment when she refused to do interview
Capital FM's Chris Stark revealed on air on Tuesday that he once almost missed out on an interview w2024-05-01
atest comment